| Dr Sudhir K Bhaskar, MD | |
|
3885 Oakwater Cir, Orlando, FL 32806-6257 | |
| (407) 851-5600 | |
| (407) 438-9585 |
| Full Name | Dr Sudhir K Bhaskar |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 35 Years |
| Location | 3885 Oakwater Cir, Orlando, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104890979 | NPI | - | NPPES |
| 3092862 | Other | FL | AETNA |
| 51359 | Other | FL | BC/BS |
| 2648881000 | Medicaid | FL | |
| 2208840 | Other | FL | UNITED HEALTHCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | ME85426 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Orlando Health | Orlando, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gastro Health, Llc | 2365440567 | 236 |
News Archive
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
Introducing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut health care spending in the United States by $54 billion over the next decade, according to new analysis from the RAND Corporation.
When cancer cells dissociate from the original tumor and migrate via the blood stream to colonize distant organs, is the main cause of cancer death.
Fracture incidence is greatly increased in individuals who undergo haematopoietic stem cell transplantation compared with the general US population, research shows.
Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.
› Verified 9 days ago
| Entity Name | Orlando Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669429577 PECOS PAC ID: 9537059084 Enrollment ID: O20040318000044 |
News Archive
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
Introducing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut health care spending in the United States by $54 billion over the next decade, according to new analysis from the RAND Corporation.
When cancer cells dissociate from the original tumor and migrate via the blood stream to colonize distant organs, is the main cause of cancer death.
Fracture incidence is greatly increased in individuals who undergo haematopoietic stem cell transplantation compared with the general US population, research shows.
Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.
› Verified 9 days ago
| Entity Name | Gastro Health, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487767133 PECOS PAC ID: 2365440567 Enrollment ID: O20061127000011 |
News Archive
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
Introducing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut health care spending in the United States by $54 billion over the next decade, according to new analysis from the RAND Corporation.
When cancer cells dissociate from the original tumor and migrate via the blood stream to colonize distant organs, is the main cause of cancer death.
Fracture incidence is greatly increased in individuals who undergo haematopoietic stem cell transplantation compared with the general US population, research shows.
Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sudhir K Bhaskar, MD 3885 Oakwater Cir, Orlando, FL 32806-6257 Ph: (407) 851-5600 | Dr Sudhir K Bhaskar, MD 3885 Oakwater Cir, Orlando, FL 32806-6257 Ph: (407) 851-5600 |
News Archive
The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.
Introducing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut health care spending in the United States by $54 billion over the next decade, according to new analysis from the RAND Corporation.
When cancer cells dissociate from the original tumor and migrate via the blood stream to colonize distant organs, is the main cause of cancer death.
Fracture incidence is greatly increased in individuals who undergo haematopoietic stem cell transplantation compared with the general US population, research shows.
Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.
› Verified 9 days ago
Vamsi Kiran Kodumuri, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 258 S Chickasaw Trl Ste 203, Orlando, FL 32825 Phone: 407-303-6588 | |
Francoeur Cadet, D.O Gastroenterology Medicare: Medicare Enrolled Practice Location: 232 N Orange Blossom Trl, Orlando, FL 32805 Phone: 407-428-5751 Fax: 407-447-7245 | |
Andrija Vidic, D.O Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2415 N Orange Ave Ste 700, Orlando, FL 32804 Phone: 407-303-2474 Fax: 407-303-0680 | |
Azin Azarfar, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 3400 Quadrangle Blvd, Orlando, FL 32817 Phone: 407-266-3627 Fax: 407-266-4911 | |
Zain Zamir, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 2501 N Orange Ave Ste 235, Orlando, FL 32804 Phone: 407-303-7169 | |
Dr. Arsenio R Rodriguez, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1745 N Mills Avenue, Orlando, FL 32803 Phone: 407-841-7151 Fax: 407-648-2259 | |
Dr. Maria R Flores, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 70 W Gore St, Suite 100, Orlando, FL 32806 Phone: 407-426-8484 Fax: 404-426-8575 |